Regional Coordinator Centre for Rare Diseases of the Friuli Venezia Giulia Region-Italy (RCCRD), University Hospital of Udine, Italy

Similar documents
The Centre for Disease Prevention and Control, Latvia

National Center for Tumor Diseases (NCT) Heidelberg, Germany

Central Manchester University Hospitals NHS Foundation Trust, UK

INSTITUTE OF CHILD HEALTH, Greece

RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA, Spain

Hospital Carlos Haya. Malaga, Spain

Ministry for Health, the Elderly and Community Care, Malta

Erasmus MC, Center for lysosomal and metabolic diseases, Netherlands

Hospital Universitario de Getafe (Getafe Universitary Hospital), Spain

Department of Medical Genetics, Medical School, University of Athens, Greece

Radboud University Nijmegen Medical Centre, department of Neurology, Netherlands

European Society of Cardiology, France

SERVICIO DE NEUROCIRUGÍA PEDIÁTRICA. HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Spain

Cystic Fibrosis Europe (CFE), Germany

Schoen Kliniken group, Schoen Klinik Hamburg Eilbek, Dept. of neurology and. neurorehabilitation, Germany

Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, SWEDEN

Castilla y leon Regional Health Service (Gerencia Regional de Salud de Castilla y León)

Riga East University hospital stationary Infectology Center of Latvia (RAKUS LIC), Latvia

VSOP, Lupus Netherlands

European Haemophilia Consortium

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

SANICADEMIA International Training Academy for health professionals

National Plans for Rare Diseases The French plan Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

ERN board of Member States

EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)

UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES

European Reference Networks (ERN) Guide for patient advocates

European Reference Networks: strategic value for the Member States. Perspective of France

ERN Assessment Manual for Applicants

WORK PLAN 2017 LAURENCE BALLIEUX NATIONAL FOCAL POINT. 1 EU 3rd HEALTH PROGRAMME

BELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD)

10 Specialist commissioning

Guidance for the Applicants: Gilead Sciences Nordic Fellowship Programme 2017

European Quality Assurance Scheme for Breast Cancer Services

APPENDIX ONE. ICAT: Integrated Clinical Assessment Tool

ECHA Helpdesk Support to National Helpdesks

Member webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016

Workshop Networking for Innovation under measure 16 in Rural Development Programmes October 2015 Tallinn, Estonia

INSIEL-FVG Region. CONFERENCE ON THE ONCE-ONLY PRINCIPLE FOR CITIZENS AND BUSINESSES 28 th November 2017

What type of research infrastructure is eligible for funding?

The Seventh Framework Programme for candidate and potential candidate countries European Regional Economic Forum Nova Gorica, 30 May 2007

Executive Report to the European Commission on newborn screening in the European Union

Implementing the 3rd Health Programme. Ingrid Keller Coordinator Health Programme Consumer, Health and Food Executive Agency

Developing a European Registry for Rare Anaemias

Building the Europe of Knowledge

ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants

ERA-NET ERA-NET. Cooperation and coordination of national or regional research and innovation activities (i.e. programmes)

Innovation and research priorities of the EEA and Norway Grants

ERC funding opportunities

Introduction to ibmg. Marco Varkevisser Director of Education

116 Help Lines for Rare Diseases

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. Report on the interim evaluation of the «Daphne III Programme »

FP7: Marie Curie Actions

The following passage wants to illustrate the insufficiencies in CF care the patients, their families and care giver struggle with:

SiS FVG - SCIENTIFIC&INNOVATION SYSTEM OF THE FRIULI VENEZIA GIULIA REGION

Jean Monnet support to associations

Guideline for Applicants. Intramural Research Funding Programs Faculty of Medicine Tübingen

G-I-N 2016 conference report

HORIZON 2020 Instruments and Rules for Participation. Elena Melotti (Warrant Group S.r.l.) MENFRI March 04th 2015

Overview on diabetes policy frameworks in the European Union and in other European countries

TEMPUS and E+ in Lebanon: The Creation of New Structures. Dr. Samer Hamzeh 18/05/2017

NORDIC COLLABORATIONS ON REGISTRIES SIMILARITIES & DIFFERENCES

European network of paediatric research (EnprEMA)

Do terms like FP6, CORDIS, Specific Programme, Call for

Summary of a Survey on the Europe 2020 Flagship Initiative Innovation Union. Executive Summary

Service charter OF C.A.L. "Dialysis Alle Vele"

WRITING A COMPETITIVE ERC CONSOLIDATOR GRANT PROPOSAL FFG-ACADEMY WEBINAR,

Programme Support to researchers for the application to the ERC programmes

EUCERD Joint Action WP7 Workshop From Centres of Expertise for Rare Diseases to European Reference Networks

CALL FOR PROPOSALS OF THE JOINT RESEARCH PROJECTS WITHIN THE EXECUTIVE PROGRAMME OF COOPERATION IN THE FIELD OF SCIENCE AND TECHNOLOGY

2nd European Reference Networks Conference 8-9 October Lisbon, Portugal. A report by: G Porto & F Courtois

European network of paediatric research (EnprEMA)

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

SCHEDULE 2 THE SERVICES

Horizon 2020 LEIT-Space

Regulation on the implementation of the European Economic Area (EEA) Financial Mechanism

Document: Report on the work of the High Level Group in 2006

Regulatory Cooperation in Europe. Natalie McCoy, CEER Secretary General INOGATE Conference - Brussels, 1 February 2013

TUITION FEE GUIDANCE FOR ERASMUS+ EXCHANGE STUDENTS Academic Year

A short paper for ENVI & IMCO MEPs Two solutions to improve recognition of specialisms in the Chapter III professions

Building a successful partnership

QUICK REFERENCE TO CALDICOTT & THE DATA PROTECTION ACT 1998 PRINCIPLES

CALL TEXT AND NATIONAL/REGIONAL REGULATIONS

Annex 3 Information and Communication Requirements EEA and Norway Grants

Norwegian Programme for Research Cooperation with China (CHINOR)

The EU Framework Programme for Research and Innovation. SEWP and Seal of excellence: fostering syenergies

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

Delegations will find below the above-mentioned Council conclusions, as endorsed by the Council (General Affairs) on 14 September 2015.

Acting Together: How to continue to provide high quality and universally accessible health services in a financially sustainable way in Europe.

European network of paediatric research (Enpr-EMA)

Save the bees!!! CALL FOR RESEARCH PROJECTS 2018 AGAINST XENOBIOTIC COMPOUNDS. Submission procedure will be in two steps: STEP 1: PREPROPOSALS

ERN IT Platform delivering the virtual link for the Networks

STUDENT AGREEMENT For the ERASMUS MUNDUS Joint Master Degree (EMJMD) in Sustainable Tropical Forestry (SUTROFOR)

European Funding Opportunities in the field of Language Teaching and Learning

United Nations Development Programme. Country: Armenia PROJECT DOCUMENT

ERASMUS MUNDUS Frequently-asked questions ACTION 2: Questions from higher education institutions Latest update: January 2011

Call for Nominations. CARLOS V European Award

New opportunities of regional /multilateral RTD cooperation The Southeast European (SEE) ERA-NET project

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

Transcription:

Regional Coordinator Centre for Rare Diseases of the Friuli Venezia Giulia Region-Italy (RCCRD), University Hospital of Udine, Italy 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: Please indicate level: 1. Respondent Profile Academic/public health and healthcare specialised institution/organisation (e.g. Institutes and University Departments of Public Health, Quality, Healthcare, Clinical Excellence) National level organisation Please indicate for what the administration is responsible: 1.1.1. Other (please specify): 1.2 Please indicate the name of your organisation or centre: Regional Coordinator Centre for Rare Diseases of the Friuli Venezia Giulia Region- Italy (RCCRD), University Hospital of Udine, Italy 1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in 1.4 Please indicate the number of EU Member States and EEA 11 countries (Norway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is 1. If need be, can we contact you by e-mail to obtain further information on your submission? 1..1 Please provide an e-mail address where we can contact bembi.bruno@aoud.sanita.fvg.it 1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): 1.7 Please provide additional contact details if needed: IT Dr. Giulia Liva, secretary responsible: +390-0432-9914 2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC).

2.1 How would you describe your organisation's knowledge of CoE and HSHC? Very high 2.1.1 Space for further comments: The RCCRD directs the Rare Diseases Regional Registry, represents FVG Region at the technical table for Rare Diseases (RD) at the Ministry of Health, is involved in 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) 2.2.1. Space for further comments: 2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans? Highly specialised healthcare provision Costs and economic evaluation Priorities, description and characteristics of CoE and HSHC Ethical analysis Social aspects Professional performance, clinical practice, quality and safety of specialized healthcare Assessment/evaluation/certification of clinical practice and healthcare providers Information system, coding Very high 2.3.1 Space for further comments: The RCCRD provides genetic and biochimical diagnosis for RD at UE level, is involved in research projects on lysosomal diseases (pathophysiology and new 2.4. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? Please specify: 2.. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare? Medical speciality Therapy for RD (enzyme, small molecules therapy) Frequently 2..1 Please describe your role in such actions/projects: The RCCRD is involved in the organization of regional and national network for RD, in Centre of Rreference certification, in epidemiological data management, 2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly

2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? 2.7.1 Space for further comments: The RCCRD is involved in an EU projects on RD registry; collaborates with EU Centres on scientific programmes of RDs management;it's Laboratory is part of an EU net for Lysosomal Disorders. 2.13. What is the scope of the network? 2.14. Which kind of network? 2.14.1 Space for further comments: 2.1. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, = very 2.1.1 Space for further comments: 3. Proposed criteria for ERN (scope, general and specific criteria) 3.1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN 3.1.1. Need of highly specialised healthcare 3.1.1.1. Complexity of the diagnosis and treatment 3.1.1.2. High cost of treatment and resources 4 3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures 3.1.2. Need of particular concentration of expertise and resources

3.1.2.1. Rare expertise/need of concentration of cases 3.1.2.2. Low prevalence/incidence/number of cases 4 3.1.2.3. Evaluated experiences of Member States 4 3.1.3. Based on high-quality, accessible and cost-effective healthcare 3.1.3.1. Evidence of the safety and favourable risk-benefit analysis 3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical) 3.1.4. Do you recommend any additional criteria or option that would effectively address the issue? 3.1.4.1 Explain your proposal in free text: 3.1.. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria? 4 Evidence of scientific activity 3.1..1 Explain your proposal in free text: Lysosomal Storage Disorders for their complexity and high cost of therapies. 3.2. General criteria of the centres wishing to join a European Reference Network 3.2.1. Organisation and management 3.2.2. Patients empowerment and centered care 3.2.3. Patient care, clinical tools and health technology assessment 3.2.4. Quality, patient safety and evaluation framework policies

3.2.. Business continuity, contingency planning and response capacity 3.2.6. Information systems, technology and e-health tools and applications 3.2.7. Overall framework and capacity for research and training 3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in 3.2.9. Do you recommend any additional option that would effectively address the issue? 3.2.9.1. Space for further comments: 4 4 No 3.3.1. Competence, experience and good outcomes and care 3.3. Specific criteria regarding the areas of expertise 3.3.2. Specific resources and organisation: 3.3.2.1. Human resources 4 3.3.2.2. Team/centre organisation 3.3.2.3. Structural conditions 3.3.2.4. Specific equipment 3.3.2.. Presence and coordination with other required complementary units or services 3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise

3.3.4. External coordination, care management and follow-up of patients 3.3.. Research, training, health technology assessment in the field of expertise 3.3.6. Specific information systems 4 3.3.7. Do you recommend any additional criteria or option that would effectively address the issue? No 3.3.7.1. Space for further comments: The RCCRD considers a priority the organization of an UE Registry of RDs as well as the creation of a EU network of Lysosomal Diseases Centre of Excellence